defects were compared across metastatic sites by Pearson's Chisquared test.
INTRODUCTION AND OBJECTIVES:
A risk stratification of Nþ prostate cancer (PCa) patients according to tumor characteristics was recently proposed (Abdollah et al. JCO 2014) . The aim of this study was to assess whether the rate of other cause mortality (OCM) differs in Nþ PCa patients according to these 5 risk-groups, after accounting for the risk of cancer specific mortality (CSM). This would allow to improve patient stratification and to identify candidates for additional therapies.
METHODS: We evaluated 1,312 Nþ PCa patients treated with radical prostatectomy and pelvic lymph node dissection at two tertiary referral centers between 1988 and 2014. Patients were stratified into the 5 established risk-groups: very low-risk (2 Nþ, and Gleason score 6); low-risk (2 Nþ, Gleason score 7-10, pT2/pT3a and negative surgical margins); intermediate-risk (2 Nþ, Gleason score 7-10 and pT3b/pT4 or SMþ); high-risk (3-4 Nþ); very high-risk (>4 Nþ). Poisson smoothed cumulative incidence methods were used to assess 8-year OCM according to risk groups, after accounting for the risk of CSM. The same analyses were performed among men who experienced BCR after RP (n¼ 633, 48.2%).
RESULTS: The median follow-up after RP was 82 months (IQR 37.1-147). During the study period, 18.1% of men died from other causes and 14.6% died from PCa. The leading cause of death at 8-year was OCM in the very low and low risk groups (12.6 and 8.3% vs. 2.5 and 7.6% for CSM, respectively). Conversely, CSM was the main cause of death in the remaining groups (Fig 1a) . When the same analyses were repeated in men who had BCR after RP, CSM was the leading cause of death in all risk-groups except in very low-risk patients, where the 8-year OCM and CSM were similar (5.9 and 5.8%, respectively; Fig. 1b) .
CONCLUSIONS: PCa is not invariably the main cause of death in all Nþ patients treated with curative intent. Patients with less aggressive disease are more likely to die from other causes. Conversely, when Nþ patients recur, they will likely succumb from PCa rather than from other causes, regardless of tumor aggressiveness. These results could help physicians sparing unnecessary treatments in Nþ men with lower likelihood of dying from PCa and to plan timely salvage treatments in virtually all Nþ men who recur Source of Funding: none
PD03-04 LONG-TERM RATES OF PROSTATE CANCER DIAGNOSIS AND ALL-CAUSE MORTALITY IN A POPULATION-BASED COHORT OF MEN WITH AN INITIALLY NEGATIVE PROSTATE BIOPSY
Rashid Sayyid*, Shabbir Alibhai, Rinku Sutradhar, Maria Eberg, Kinwah Fung, David Urbach, Neil Fleshner, Toronto, Canada INTRODUCTION AND OBJECTIVES: Transrectal ultrasoundguided prostate biopsies (TRUS-Bx) have a high false-negative rate, and thus men with a negative TRUS-Bx frequently undergo repeat biopsies leading to subsequent diagnoses of prostate cancer (PCa). Long-term outcome data on such patients is lacking, as previous studies have only reported the short-term rates of PCa diagnosis in small cohorts of men with a negative TRUS-Bx. Our objective was to determine both the long-term rates of PCa diagnosis and all-cause mortality in a large, population-based cohort of men with a single negative TRUS-Bx.
METHODS: This was a retrospective, population-based study of 124,067 men who had an initially negative TRUS-Bx in Ontario, Canada between April 1994 and March 2015. All included men were older than 40 years and had no prior history of PCa. Using data from the Ontario Health Insurance Plan, Ontario Cancer Care Registry, and Registered Persons Database, housed at the Institute of Clinical and Evaluative Sciences, we were able to determine the 5, 10, 15, and 20 year rates of PCa diagnosis and all-cause mortality in such men.
RESULTS: Mean age at date of first negative TRUS-Bx was 63.55 years (SD¼8.75). Total follow-up time was 974986.07 person-years, with mean follow-up per patient at 7.86 years (SD¼5.37). The total number of subsequent PCa diagnoses was 21,869, accounting for an incidence rate of 22.25 per 1000 person-years. The 5, 10, 15, and 20-year rates of PCa diagnosis were 0.130, 0.187, 0.220, and 0.239, respectively. The total number of deaths in our cohort was 21,375, accounting for a death incidence rate of 21.92 per 1000 person-years. The 5, 10, 15, and 20-year all-cause mortality rates were 0.068, 0.155, 0.260, and 0.380, respectively.
CONCLUSIONS: Based upon these long-term populationbased data, a significant proportion of men with an initially negative TRUS-Bx subsequently receive a diagnosis of PCa, with risk of diagnosis continuously rising. These data suggest that long term follow up of at risk men is warranted. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e57
